12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

AiCuris, Merck deal

AiCuris granted Merck exclusive, worldwide rights to AiCuris' human cytomegalovirus (CMV) portfolio, including letermovir ( AIC246). AiCuris will receive €110 million ($142.5 million) up front and is eligible to receive up...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >